P53 Antigen Modulators - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “P53 Antigen Modulators - Pipeline Insight, 2022” report provides comprehensive insights about 7+ companies and 8+ pipeline drugs in P53 Antigen Modulators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
P53 Antigen Modulators: Overview
p53 is an important tumor-suppressor protein that is altered in most cancers. The p53 protein acts as a pivotal suppressor of inappropriate cell proliferation. By initiating suppressive effects through induction of apoptosis, cell senescence, or transient cell-cycle arrest, p53 plays an important role in cancer suppression, developmental regulation, and aging. Loss or mutation of p53 in the tumor has been shown to modulate immune recognition through mechanisms such as decreased MHC-I presentation and increased recruitment of suppressive myeloid cells and Tregs. However, p53 also has a crucial role in the stromal compartment, where it can play diverse roles in inhibiting or supporting tumor development. A number of p53 modulators, consisting of synthetic peptides, organic compounds, and natural products, have been identified that directly or indirectly restore p53 functions and reverse progression of preneoplastic lesions and uncontrolled tumor growth. The mechanism(s) of action of these p53 modulators is being extensively investigated.
Report Highlights
This segment of the P53 Antigen Modulators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
P53 Antigen Modulators Emerging Drugs
Further product details are provided in the report……..
P53 Antigen Modulators: Therapeutic Assessment
This segment of the report provides insights about the different P53 Antigen Modulators drugs segregated based on following parameters that define the scope of the report, such as:
P53 Antigen Modulators: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses P53 Antigen Modulators therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging P53 Antigen Modulators drugs.
P53 Antigen Modulators Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “P53 Antigen Modulators - Pipeline Insight, 2022” report provides comprehensive insights about 7+ companies and 8+ pipeline drugs in P53 Antigen Modulators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
P53 Antigen Modulators: Overview
p53 is an important tumor-suppressor protein that is altered in most cancers. The p53 protein acts as a pivotal suppressor of inappropriate cell proliferation. By initiating suppressive effects through induction of apoptosis, cell senescence, or transient cell-cycle arrest, p53 plays an important role in cancer suppression, developmental regulation, and aging. Loss or mutation of p53 in the tumor has been shown to modulate immune recognition through mechanisms such as decreased MHC-I presentation and increased recruitment of suppressive myeloid cells and Tregs. However, p53 also has a crucial role in the stromal compartment, where it can play diverse roles in inhibiting or supporting tumor development. A number of p53 modulators, consisting of synthetic peptides, organic compounds, and natural products, have been identified that directly or indirectly restore p53 functions and reverse progression of preneoplastic lesions and uncontrolled tumor growth. The mechanism(s) of action of these p53 modulators is being extensively investigated.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence P53 Antigen Modulators R&D. The therapies under development are focused on novel approaches for P53 Antigen Modulators.
This segment of the P53 Antigen Modulators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
P53 Antigen Modulators Emerging Drugs
- Eprenetapopt: Aprea
- Pidnarulex: Senhwa Biosciences
Further product details are provided in the report……..
P53 Antigen Modulators: Therapeutic Assessment
This segment of the report provides insights about the different P53 Antigen Modulators drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on P53 Antigen Modulators
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
P53 Antigen Modulators: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses P53 Antigen Modulators therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging P53 Antigen Modulators drugs.
P53 Antigen Modulators Report Insights
- P53 Antigen Modulators Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing P53 Antigen Modulators drugs?
- How many P53 Antigen Modulators drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for P53 Antigen Modulators?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the P53 Antigen Modulators therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for P53 Antigen Modulators and their status?
- What are the key designations that have been granted to the emerging drugs?
- Aprea
- Quark-Pharmaceuticals
- Shenzhen SiBiono GeneTech
- H. Lee Moffitt Cancer Center and Research Institute
- Statera BioPharma
- Senhwa Biosciences
- PMV Pharmaceuticals
- Eprenetapopt
- Teprasiran
- p53 gene therapy
- INGN 225
- APR-548
- CBL 137
- Pidnarulex
- Research programme: small molecule therapeutics
Introduction
Executive Summary
P53 Antigen Modulators: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
P53 Antigen Modulators – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
P53 Antigen Modulators companies’ collaborations, Licensing, Acquisition -Deal Value Trends
P53 Antigen Modulators Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Eprenetapopt: Aprea
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Pidnarulex: Senhwa Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
APR-548: Aprea
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
P53 Antigen Modulators Key Companies
P53 Antigen Modulators Key Products
P53 Antigen Modulators- Unmet Needs
P53 Antigen Modulators- Market Drivers and Barriers
P53 Antigen Modulators- Future Perspectives and Conclusion
P53 Antigen Modulators Analyst Views
P53 Antigen Modulators Key Companies
Appendix
Executive Summary
P53 Antigen Modulators: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
P53 Antigen Modulators – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
P53 Antigen Modulators companies’ collaborations, Licensing, Acquisition -Deal Value Trends
P53 Antigen Modulators Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Eprenetapopt: Aprea
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Pidnarulex: Senhwa Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
APR-548: Aprea
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
P53 Antigen Modulators Key Companies
P53 Antigen Modulators Key Products
P53 Antigen Modulators- Unmet Needs
P53 Antigen Modulators- Market Drivers and Barriers
P53 Antigen Modulators- Future Perspectives and Conclusion
P53 Antigen Modulators Analyst Views
P53 Antigen Modulators Key Companies
Appendix